Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001654954-17-005032
Filing Date
2017-05-23
Accepted
2017-05-23 17:40:09
Documents
1
Period of Report
2017-05-19

Document Format Files

Seq Description Document Type Size
1 FORM 4 LATKIN section16.html 4  
1 FORM 4 LATKIN section16.xml 4 4223
  Complete submission text file 0001654954-17-005032.txt   5693
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 152 W. 57TH STREET 4TH FLOOR NEW YORK NY 10019
Business Address
Latkin Jed (Reporting) CIK: 0001554593 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35076 | Film No.: 17864851